Dyne Therapeutics (DYN) Stifel 2026 Virtual CNS Forum summary

Strategic outlook and pipeline development

• 2026 is positioned as a breakout year, with validation of clinical and commercial progress expected.

• Transitioning to a fully integrated biotech company, aiming for commercial launch and market transformation in DMD by 2026–2027.

• Eight clinical programs are planned over the next few years, including DMD, DM1, four additional DMD exons, FSHD, and Pompe.

• The FORCE platform enables expansion into multiple indications with high probability of success for new exons.

• FSHD is the next product expected to enter the clinic.

DMD program and regulatory progress

• Positive top-line results for Z-rostudirsen in exon 51 DMD showed sustained functional improvement and robust dystrophin increases, meeting primary endpoints.

• Functional improvements were observed across six endpoints, with statistical significance in time to rise and ten-meter walk/run velocity.

• Long-term data at 24 months confirmed continued functional gains; safety profile remains favorable after 1,400+ doses.

• Regulatory alignment includes Breakthrough Therapy designation, placebo-controlled data, and a large safety database, supporting confidence in BLA submission for DMD in Q2.

• Priority Review is expected for the DMD BLA.

Commercial readiness and market strategy

• Commercial launch preparations include hiring experienced leadership and building a team with rare disease launch expertise.

• The target market is well-defined, with most DMD patients concentrated in 100 muscle centers, enabling a capital-efficient sales approach.

• Inventory and supply chain are being secured with dual sourcing and experienced operations leadership.

• Product differentiation is based on improved dosing schedule and functional benefits compared to existing therapies.